Is Thymalin approved or legal?

Thymalin is an approved prescription medicine in Russia (marketed as Тималин) and has been used clinically there for decades. However, it is not approved by the FDA, EMA, or most Western regulators. Outside Russia and a small number of post-Soviet markets, it is available only as a research compound labeled for research use only and is not licensed for human therapeutic use.

What is the difference between Thymalin and Thymosin Alpha-1?

Thymosin Alpha-1 is a fully synthetic, single-sequence peptide (Tα1, 28 amino acids) that is FDA-approved as Zadaxin in some countries and well-characterized pharmacokinetically. Thymalin is a bovine thymus extract containing a mixture of small peptides; it is not a single defined molecule. Both are studied for immune modulation and thymic support, but they differ in origin, composition, regulatory status, and evidence base.

What dose is used and how often?

The Russian clinical protocol described in Khavinson's studies is 5–10 mg intramuscularly per day for 5–10 consecutive days, repeated once or twice per year over multiple years. Community use mirrors these figures. There is no validated Western clinical dose, and this information is a research reference, not dosing advice.

What is the strongest evidence for Thymalin?

The most cited finding is a long-term cohort study (Khavinson and Morozov, 2003) reporting substantially reduced mortality in elderly subjects treated with Thymalin and Epitalon over 6–8 years. While the outcome is striking, the study was non-blinded and non-randomized, and it has not been independently replicated. Immune restoration effects (T-cell counts, NK activity) are also reported but carry the same methodological limitations.

Can Thymalin be taken orally?

The published clinical literature describes intramuscular injection as the standard route. Like most peptide mixtures, Thymalin is susceptible to gastrointestinal degradation, and oral bioavailability is not established. Some newer synthetic peptide bioregulators derived from thymus peptide research are available as oral formulations, but Thymalin itself is not validated for oral use.

Is Thymalin the same as Thymosin?

No. Thymosin refers to a family of polypeptides originally isolated from thymus tissue (including Thymosin Alpha-1 and Thymosin Beta-4/TB-500). Thymalin is a distinct bovine thymus extract developed by the Russian bioregulator research program. They share the general concept of thymus-derived immunomodulatory peptides, but are different compounds with separate research histories and compositions.

Longevity

Thymalin

Also known as: Timalin, Тималин, Thymus peptide bioregulator, bovine thymus extract peptides

Polypeptide bioregulator derived from bovine thymus gland, studied in Russia for immune restoration and longevity; most evidence is from a single research group, with no FDA or...

Last updated July 11, 2026

Buy Thymalin

Overview

Thymalin is a peptide bioregulator — a low-molecular-weight polypeptide mixture extracted from the thymus glands of calves — developed in the Soviet Union during the 1970s and 1980s by Vladimir Khavinson, Vladimir Morozov, and colleagues at what is now the St. Petersburg Institute of Bioregulation and Gerontology. Unlike fully synthetic peptides, Thymalin is a natural extract containing multiple small peptides that together are thought to restore thymic signaling, with Khavinson's group identifying short di- and tripeptide sequences (including Lys-Glu and related fragments) as the probable active components. In Russia and some Eastern European countries, Thymalin has a long history of prescription clinical use, where it is licensed as an immunomodulator. Outside those markets it is not approved by the FDA, EMA, or most Western regulators and is classified as a research compound. The biological rationale is straightforward: the thymus involutes progressively from early adulthood, contributing to a decline in naïve T-cell output and immune competence that is considered a central feature of immunosenescence (age-related immune decline). Restoring thymic peptide signaling is hypothesized to slow or partially reverse this process. Published studies report improvements in immune parameters, reductions in age-associated disease incidence, and reduced mortality in elderly cohorts treated over many years — findings that are biologically plausible but come almost entirely from one institution and have not been replicated in independent, double-blind, placebo-controlled trials in Western literature. This entry is a research reference only. It is not medical advice and does not endorse human use.

How it works

Thymalin's principal proposed mechanism is peptide bioregulation of thymic function. The thymus-derived peptides are thought to act as short-range signaling molecules that bind to chromatin and regulate gene expression in immune progenitor cells, particularly T-lymphocyte precursors. The core hypothesis from Khavinson's group is that these peptides act as gene-expression regulators — complementary to the DNA promoter regions — enabling restoration of thymosin- and thymulin-mediated differentiation signals that decline with age. At the cellular level, Thymalin preparations are reported to normalize the ratio of CD4+ to CD8+ T-lymphocytes, restore natural killer (NK) cell activity, and increase production of interleukins important for adaptive immunity. Some studies report effects on oxidative stress markers and on neuroendocrine-immune crosstalk. A recurring theme in the bioregulator framework is that these peptides are effective at low concentrations (nanomolar to picomolar), consistent with a signaling rather than pharmacological mechanism, though independent verification of these molecular details at scale is limited.

Researched effects

Clinical Reported reduction in mortality and age-related disease incidence in elderly cohorts over multi-year treatment programs
Clinical Restoration of T-lymphocyte counts and CD4/CD8 ratios in immunosenescent or immunodeficient patients
Clinical Improved NK cell activity and general cellular immune competence in aged or diseased patients
Clinical Reduced incidence of respiratory and infectious illness in elderly subjects during follow-up
Clinical Combined courses of Thymalin and Epitalon (pineal extract) associated with substantially reduced mortality in long-term elderly cohort data
Preclinical Restoration of age-impaired immune function in rodent models
Anecdotal Widely reported improvements in energy, immune resilience, and general wellbeing in the peptide-bioregulator community

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No regulator-established human therapeutic dosing exists outside Russia. In the Russian clinical literature (Khavinson and Morozov group), Thymalin was typically administered by intramuscular injection in intensive short courses: 5–10 mg daily for 5–10 consecutive days, with courses repeated once or twice yearly over multiple years. This protocol is described in several Russian-origin publications translated or summarized in English-language journals. These dosing figures come from non-blinded, single-group studies and should not be treated as validated clinical guidance in contexts where the compound is not a licensed medicine.

Community-reported dosing (anecdotal)

ANECDOTAL / RESEARCH-REFERENCE ONLY — not medical advice or instruction. Community discussion (peptide forums, longevity research groups, and r/Peptides-adjacent spaces) has adopted the same figures described in the Russian clinical protocols: typically 5–10 mg via intramuscular injection daily for 5–10 days, run once or twice per year. Some users report combining Thymalin with Epitalon in a broader "peptide bioregulator" longevity cycle, following the general structure of the Khavinson multi-year programs. These figures are unverified community conventions derived from research literature, not independently validated safe or effective doses.

Half-life: Not well characterized in English-language pharmacokinetic studies. Thymalin is a polypeptide mixture of small fragments; constituent peptides are expected to have short plasma half-lives (likely minutes to low hours), consistent with other peptide bioregulators in this class. Biological effects reported in Russian clinical studies appear to outlast measurable peptide presence, which the bioregulator framework attributes to gene-regulatory rather than sustained-circulating-level effects.
Routes: intramuscular

Safety & side effects

Long-term human safety data from independent, blinded, Western-conducted studies are absent. The available Russian-origin literature and reported clinical use spanning decades in Russia describe a generally favorable tolerability profile; adverse events reported are mainly injection-site reactions (redness, mild swelling). No serious adverse events attributable to Thymalin are prominent in the English-language literature, but the methodological limitations of the source studies mean this should not be taken as a clean safety clearance. Thymalin is an immunomodulator, and immune stimulation is theoretically not appropriate in autoimmune conditions or in the context of organ transplant immunosuppression. As with any peptide derived from bovine tissue, theoretical risk of contamination with infectious agents (e.g., prions) exists, though this is not specifically reported. Product purity and sterility are significant real-world risks for any material sold as a research compound outside of the Russian pharmaceutical supply chain where it is a licensed medicine. Thymalin is not approved by the FDA or EMA. Outside Russia and a small number of other post-Soviet markets, it is available only for research use only and should be treated as an experimental compound.

Research summary

The evidence base for Thymalin is unusual by Western standards: it consists largely of clinical studies — including long-term cohort data — but almost all originate from a single research group (Khavinson, Morozov, and colleagues) and lack the blinding, randomization, and independent replication expected of contemporary clinical trials. The flagship human study (Khavinson and Morozov, Neuroendocrinology Letters, 2003) followed 266 elderly subjects and reported that treatment with thymic peptides (Thymalin) and pineal peptides (Epithalamin/Epitalon) over 6–8 years was associated with substantially reduced mortality compared with untreated controls — an effect attributed to combined immune and neuroendocrine restoration. The mortality differences were striking but come from a non-blinded, non-randomized design and were not replicated in an independent cohort. Anisimov and Khavinson (Biogerontology, 2010) provide a broader review of peptide bioregulation across multiple compounds, summarizing decades of Russian research showing consistent patterns of immune restoration, reduced age-associated pathology, and lifespan extension in both animals and elderly human cohorts. The 1997 paper by Morozov and Khavinson (International Journal of Immunopharmacology) specifically reviews thymic peptides — both natural extracts and synthetic derivatives — as therapeutics for immune dysfunction, establishing the mechanistic rationale. The key limitation throughout is a lack of independent replication. No large, randomized, double-blind, placebo-controlled trial of Thymalin in an independent Western research setting has been published. The compound is approved and used in Russia on the basis of its accumulated Soviet- and post-Soviet-era clinical literature, and that body of work is internally consistent, but it does not meet the evidentiary bar that Western regulators require. Claims of human longevity extension or mortality reduction should therefore be treated as promising but unconfirmed hypotheses rather than established facts.

FAQ

Is Thymalin approved or legal?: Thymalin is an approved prescription medicine in Russia (marketed as Тималин) and has been used clinically there for decades. However, it is not approved by the FDA, EMA, or most Western regulators. Outside Russia and a small number of post-Soviet markets, it is available only as a research compound labeled for research use only and is not licensed for human therapeutic use.
What is the difference between Thymalin and Thymosin Alpha-1?: Thymosin Alpha-1 is a fully synthetic, single-sequence peptide (Tα1, 28 amino acids) that is FDA-approved as Zadaxin in some countries and well-characterized pharmacokinetically. Thymalin is a bovine thymus extract containing a mixture of small peptides; it is not a single defined molecule. Both are studied for immune modulation and thymic support, but they differ in origin, composition, regulatory status, and evidence base.
What dose is used and how often?: The Russian clinical protocol described in Khavinson's studies is 5–10 mg intramuscularly per day for 5–10 consecutive days, repeated once or twice per year over multiple years. Community use mirrors these figures. There is no validated Western clinical dose, and this information is a research reference, not dosing advice.
What is the strongest evidence for Thymalin?: The most cited finding is a long-term cohort study (Khavinson and Morozov, 2003) reporting substantially reduced mortality in elderly subjects treated with Thymalin and Epitalon over 6–8 years. While the outcome is striking, the study was non-blinded and non-randomized, and it has not been independently replicated. Immune restoration effects (T-cell counts, NK activity) are also reported but carry the same methodological limitations.
Can Thymalin be taken orally?: The published clinical literature describes intramuscular injection as the standard route. Like most peptide mixtures, Thymalin is susceptible to gastrointestinal degradation, and oral bioavailability is not established. Some newer synthetic peptide bioregulators derived from thymus peptide research are available as oral formulations, but Thymalin itself is not validated for oral use.
Is Thymalin the same as Thymosin?: No. Thymosin refers to a family of polypeptides originally isolated from thymus tissue (including Thymosin Alpha-1 and Thymosin Beta-4/TB-500). Thymalin is a distinct bovine thymus extract developed by the Russian bioregulator research program. They share the general concept of thymus-derived immunomodulatory peptides, but are different compounds with separate research histories and compositions.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.